Kelowna, British Columbia – TheNewswire - January 12, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer (“CEO”) Richard Christopher as a strategic update to all stakeholders. CEO Letter to Stakeholders  Dear Fellow Stakeholders,  I’m truly honored to deliver Lexaria’s Annual Letter from the CEO following my first full year in the position.  I’m ...

Summary of Viatris Conference Call Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Event**: UBS Healthcare Conference - **Date**: November 11, 2025 Key Updates and Financial Performance - Viatris reported a positive momentum in business with an expected operational revenue growth of **2-3%** for 2025, excluding Indor [4][80] - The company is on track to return over **$1 billion** to shareholders, including **$500 million** in share repurchases for the year [4][80] New Product Launches - Anticipated new product revenue is projected to be in the range of **$450 million to $550 million** annually, driven by existing products and upcoming launches [6][4] - Key products contributing to this revenue include: - **Iron sucrose** - **Glucagon** - **Paclitaxel** - Upcoming launches: **Liraglutide**, **Effexor GAD**, **Sotagliflozin** [6][4] Geographic Performance - **North America**: - Experienced competition in generic products, particularly **XULANE LO** [17][22] - Decline primarily attributed to the impact of Indor [19][22] - Strong double-digit growth noted in products like **Breyna** and **Uptravi** [22][22] - **Emerging Markets**: - Strong growth driven by established brand business, particularly in **Turkey**, **Mexico**, and **emerging Asia** [23][23] - Stabilization of lower-margin ARV products has supported growth in the generics business [23][23] - **Japan**: - Facing normal price regulations but focusing on adding innovative assets to stabilize and grow the business [26][26] - Recent acquisition of **Pitolisant** and **Spidea** expected to enhance the portfolio [26][26] - **China**: - Achieved **9% operational growth** driven by a diversified commercial model and strong brand demand [28][28] - Over **10,000 customers** across various channels, with expectations for low to mid-single-digit growth over time [31][31] Pipeline and Future Products - Excitement around **fast-acting meloxicam** as a non-opioid alternative for acute pain management, targeting a launch in the second half of **2026** [34][41] - Anticipated FDA filings for several products, including **Effexor GAD** and **Salatogrel**, with enrollment for Salatogrel on track to complete by the end of **2026** [51][52] Indor Remediation and Strategic Review - Progress on remediation efforts for Indor, with operational readiness for reinspection expected in **2026** [54][54] - An enterprise-wide strategic review initiated to ensure sustainable growth, with details expected in **Q1 2026** [60][60] Capital Allocation Strategy - Viatris maintains a balanced capital allocation strategy, focusing on business development and capital return, with a **50/25/25** framework [71][71] - The company is looking for opportunities to invest in durable, higher-margin innovative assets, particularly in the U.S. market [73][73] Conclusion - Viatris is optimistic about its position going into **2026**, with a focus on executing its strategic priorities, enhancing its product pipeline, and addressing challenges in various markets [80][80]

Core Insights - The article discusses two telehealth stocks, Hims & Hers Health and Doximity, which have shown significant growth and potential for future returns in the healthcare sector [2]. Hims & Hers Health - Hims & Hers Health has experienced a stock price increase of over 200% in the past 12 months, significantly outperforming the S&P 500, which rose about 18% during the same period [3]. - The company's growth was driven by its ability to offer affordable compounded GLP-1 drugs for weight loss, although it can no longer mass-produce these drugs due to the FDA declaring the shortage resolved [5]. - Hims & Hers is diversifying its offerings beyond weight loss, focusing on sexual health, hair loss, dermatology, mental health, and primary care, with most revenue coming from recurring subscriptions [6]. - The acquisition of Zava, a European digital health platform, is expected to enhance investor confidence and expand Hims & Hers' market reach into the U.K., Ireland, France, and Germany, with plans to launch in Canada in 2026 [7][8]. - The company reported a 110% year-over-year revenue growth in Q1 and generated approximately $50 million in free cash flow [8]. Doximity - Doximity has seen its shares increase by over 100% in the past year, positioning itself as the largest digital platform for U.S. medical professionals [9]. - The platform serves as a professional network for healthcare professionals, offering tools for communication, news, and career management, including telehealth solutions [10]. - Doximity provides free access to its services for healthcare professionals, generating revenue through advertising and selling information to pharmaceutical manufacturers and healthcare systems [11][12]. - In fiscal 2025, Doximity reported a 20% revenue increase to $570.4 million, with net income rising 51% year-over-year to $223.2 million and free cash flow increasing by 50% to $266.7 million [13].

Industry Overview - The GLP-1 weight loss and diabetes control sector is currently the fastest growing pharmaceutical sector globally, with revenue expectations exceeding $100 billion annually [2] - Updated projections indicate that the GLP-1 industry could generate over $156 billion in revenue by 2030, with a significant growth of 31% expected in 2025, reaching $70.1 billion [3] Challenges in the GLP-1 Sector - The GLP-1 industry faces significant challenges due to unwanted adverse effects, particularly gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation [4] - Discontinuation rates among GLP-1 users with type 2 diabetes are high, with studies showing that 47% to 64% of users stop their medication within 1 to 2 years, primarily due to gastrointestinal adverse effects [5][6] Company Innovations - Lexaria Bioscience Corp. has developed DehydraTECH technology, which aims to reduce side effects associated with GLP-1 drugs, potentially improving patient retention and industry growth [8][9] - DehydraTECH has shown promise in clinical testing for reducing gastrointestinal adverse effects in the top GLP-1 drugs, including semaglutide, tirzepatide, and liraglutide [10] Strategic Initiatives - Lexaria is pursuing a multi-faceted strategy to attract pharmaceutical companies to adopt its DehydraTECH technology, evidenced by a material transfer agreement with a pharmaceutical company announced in September 2024 [11]

Core Viewpoint - Hims & Hers Health has demonstrated strong revenue growth and profitability, but faces skepticism from investors due to contracting gross margins and high marketing expenses [3][15]. Financial Performance - Q1 revenue reached $586 million, more than doubling year-over-year, exceeding the forecast of $530 million to $550 million [5][12]. - Monthly online revenue per subscriber increased by 53% to $84, with total subscribers rising by 38% to nearly 2.4 million [5][12]. - Adjusted EBITDA surged to $91 million from $32 million a year ago, with adjusted EPS at $0.20, surpassing the analyst consensus of $0.12 [11][12]. - Operating cash flow increased over fourfold to $109 million, while free cash flow rose to $50 million [11][12]. Growth Drivers - The company expects $725 million in revenue from weight loss drugs this year, with a robust 30% growth outside of GLP-1 weight loss drugs [7][8]. - Hims & Hers plans to expand its personalized treatment offerings, with 80% of dermatology patients now using personalized solutions [6][12]. - Long-term guidance includes projected revenue of $2.3 billion to $2.4 billion for 2025, and a forecast of at least $6.5 billion in revenue by 2030, indicating a CAGR of about 22% from 2026 to 2030 [12][13]. Marketing and Margins - Marketing expenses soared by 77% to $231 million, constituting 39% of revenue, down from 47% a year ago [10][12]. - Gross margin contracted by approximately 900 basis points to 73% from 82% a year ago, with expectations for a sequential increase in the next quarter [9][12]. Investor Sentiment - The stock has shown a year-to-date increase of around 108%, but is down about 27% from earlier highs [2]. - The company's performance has led to a divided sentiment among investors, with bulls focusing on revenue growth and bears concerned about margin contraction and marketing spend [14][15].

Financial Data and Key Metrics Changes - Revenue for the first quarter of 2025 grew 111% year over year to $586 million, with adjusted EBITDA increasing to $91 million, nearly tripling from the same quarter last year [12][23][30] - Subscriber base reached nearly 2.4 million, reflecting a year-over-year increase of 38% [12][23] - Monthly online revenue per average subscriber climbed to $84, up more than 50% year over year [29] Business Line Data and Key Metrics Changes - Over 1.4 million subscribers are now using personalized solutions, with over 80% of subscribers in dermatology benefiting from personalized solutions [13][14] - Weight loss has become one of the largest specialties, with the introduction of liraglutide and a collaboration with Novo Nordisk to offer branded Wegovy [15][28] - The number of subscribers utilizing daily offerings in sexual health has more than doubled year over year, now representing nearly 40% of sexual health subscribers [26][64] Market Data and Key Metrics Changes - The company is seeing strong momentum in the weight loss category, targeting $725 million in revenue for the year [54] - The platform is positioned to address the needs of over 100 million Americans impacted by obesity [28] - The company is expanding its reach into the UK and other global markets, indicating a universal demand for convenient, customized healthcare [12][19] Company Strategy and Development Direction - The company aims to deepen personalization capabilities and expand into new specialties, including low testosterone and menopause support [10][19] - A focus on building strategic partnerships to create a curated healthcare ecosystem is emphasized [11][16] - The long-term financial objective is to achieve at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 [8][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver long-term growth, citing strong execution and a solid foundation [5][22] - The transition to more premium daily products is expected to drive durable growth, despite potential near-term volatility [27][39] - Management anticipates continued strong growth across tenured offerings, with a focus on personalized solutions [38][40] Other Important Information - The company has invested $59 million in CapEx to expand operations and enhance fulfillment capabilities [34][35] - A new Chief Operating Officer, Nadir Khabani, has been appointed to help scale operations [20] - The company is committed to maintaining a rigorous capital allocation framework with a payback period of less than a year [40] Q&A Session Summary Question: Can you elaborate on the future roadmap Hims and Hers and Novo Nordisk are developing together? - Management expressed excitement about the collaboration with Novo Nordisk and the potential for future offerings across categories and geographies [43][44] Question: What type of longevity product is the team looking to build with the recent acquisition of the peptide facility? - The focus is on expanding access to innovative peptide treatments for a broader population, making cutting-edge care more affordable [48][50] Question: Can you touch on the key drivers for the weight loss category and how personalized offerings are performing? - Management highlighted the strength of personalized offerings and the recent launches that are expected to help meet or exceed revenue targets [53][56] Question: What initiatives are in place to reaccelerate growth in the sexual health vertical? - The company is transitioning to more daily, multi-action care solutions, which are expected to enhance customer retention and engagement [62][64] Question: How does the company approach the opportunity for growth in personalized offerings versus brand partnerships? - Management emphasized the additive nature of personalized offerings and the importance of providing choices for consumers [70][74] Question: What does retention look like for the subscriber base during the transition period? - Management noted that many subscribers are transitioning to various options, including personalized and branded treatments, with a focus on maintaining engagement [77][81]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 grew 111% year over year to $586 million, with adjusted EBITDA increasing to $91 million, nearly tripling from the same quarter last year [21][28] - Subscriber base reached nearly 2.4 million, reflecting a year-over-year increase of 38% [21][22] - Monthly online revenue per average subscriber climbed to $84, up more than 50% year over year [27] Business Line Data and Key Metrics Changes - The weight loss specialty is projected to generate $725 million in revenue this year, driven by the launch of liraglutide and a collaboration with Novo Nordisk [55] - Over 80% of subscribers in dermatology are benefiting from personalized solutions, contributing to nearly 50% year-over-year subscriber growth in that specialty [12][13] - The number of subscribers utilizing daily offerings in sexual health has more than doubled year over year, now representing nearly 40% of sexual health subscribers [23][62] Market Data and Key Metrics Changes - The company is expanding its platform globally, with early traction in the UK indicating potential for scaling its services internationally [11] - The collaboration with Novo Nordisk is expected to enhance access to effective obesity care, addressing the needs of over 100 million Americans impacted by obesity [26] Company Strategy and Development Direction - The company aims to deepen personalization capabilities and expand into new specialties, including low testosterone and menopause support [7][17] - A focus on building strategic partnerships to create a curated healthcare ecosystem is central to the company's growth strategy [10][15] - The long-term financial objective is to achieve at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030 [6][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver long-term growth, citing strong execution and a solid foundation [20][41] - The transition to more premium daily products is expected to drive durable growth, despite potential near-term volatility [24][36] - Management anticipates continued strong growth across tenured offerings, with a focus on mental health and dermatology [37] Other Important Information - The company has invested $59 million in CapEx to expand operations and enhance personalized offerings [32][33] - A new Chief Operating Officer, Nadir Khabani, has been appointed to help scale operations [18] Q&A Session Summary Question: Can you elaborate on the future roadmap Hims and Hers and Novo Nordisk are developing together? - The collaboration is seen as a blueprint for future opportunities across categories and geographies, with a shared vision for the future of healthcare [44][46] Question: What type of longevity product is the team looking to build with the recent acquisition of the peptide facility? - The focus is on broadening access to innovative peptide treatments for pain management, recovery, and longevity, making them accessible to a wider population [48][50] Question: What are the key drivers for the weight loss category and how are personalized offerings performing? - The company is pleased with the strength in the weight loss specialty, with new offerings and partnerships expected to help meet or exceed revenue targets [53][55] Question: How do you approach the opportunity for growth in personalized offerings versus brand partnerships? - The company aims to provide personalized solutions where clinically necessary, while also offering a range of options for consumers [70][72] Question: What are the retention rates for subscribers transitioning from commercial doses to personalized doses? - Specific retention rates were not disclosed, but the company emphasizes the importance of providing choices for patients based on clinical needs [80][82]

Core Insights - Novo Nordisk is expanding access to its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro, and Life MD, as supply shortages have eased in the U.S. [1][2] - Hims & Hers shares surged 40% in premarket trading, while Novo Nordisk's stock rose 3% following the announcement [2]. Company Strategies - Novo Nordisk aims to capture more patients by collaborating with telehealth companies, as compounding pharmacies face legal restrictions on producing cheaper, unapproved versions of Wegovy [2][3]. - The partnerships with telehealth providers are designed to create a seamless experience for patients, allowing them to access Wegovy directly from their providers [4]. Pricing and Accessibility - Wegovy will be offered at $499 per month through Novo Nordisk's direct-to-consumer online pharmacy, which is about half of its usual list price for uninsured patients [5]. - Hims & Hers will provide Wegovy starting at $599 per month, which includes additional services such as 24/7 care and nutritional guidance [5][6]. Market Context - Hims & Hers has previously offered compounded versions of semaglutide but is now transitioning to the branded Wegovy due to regulatory changes [9]. - The FDA has set deadlines for compounding pharmacies to cease the production of unapproved versions of semaglutide, impacting the availability of alternatives [10].

Core Viewpoint - Hims & Hers Health has announced the offering of Eli Lilly's Zepbound, a weight loss drug, which is seen as a significant development despite concerns about its potential impact on the company's growth [1][5][9] Group 1: Product Offerings - Hims & Hers Health will now provide Zepbound, which has shown an average weight loss of around 21% at the highest dose, outperforming Novo Nordisk's Wegovy, which has an average weight loss of 15% [2][4] - The company will also offer liraglutide, another weight loss treatment, priced at $299 per month, significantly lower than Zepbound's $1,899 per month [10][11] Group 2: Market Reaction - Following the announcement of Zepbound, Hims & Hers shares rose by 5%, indicating positive market sentiment [2] - However, after the FDA announced the end of the semaglutide shortage, Hims' shares plummeted by nearly 26%, highlighting the volatility in the company's stock performance [4][5] Group 3: Competitive Landscape - Eli Lilly clarified that it has no affiliation with Hims & Hers, suggesting that Hims is acting merely as a middleman without unique business advantages [7][8] - The pricing strategy for Zepbound raises concerns, as it is significantly higher than Eli Lilly's direct offering, which could deter potential customers [8][9] Group 4: Future Growth Potential - The addition of liraglutide may cater to a niche market for patients looking to lose smaller amounts of weight, potentially expanding Hims' subscriber base [12][13] - Overall, the recent announcements are not seen as groundbreaking, but they may help maintain interest in Hims' weight loss offerings [13]